Table of Contents
Introduction
New York, NY – January 20, 2025 – Global Preimplantation Genetic Testing Market size is expected to be worth around US$ 1648.6 Million by 2033 from US$ 756.6 Million in 2023, growing at a CAGR of 8.1% during the forecast period from 2024 to 2033. With a market share over 36.4%, North America held a strong lead in 2023, reaching US$ 235.4 Million in revenue.
The Preimplantation Genetic Testing (PGT) market is poised for significant growth, driven by advancements in reproductive health technologies and a growing demand for precision medicine in fertility treatments. PGT, a crucial technique used in conjunction with in vitro fertilization (IVF), enables the screening of embryos for genetic disorders before implantation, reducing the risk of inherited diseases and improving pregnancy success rates.
The global market for PGT is expanding due to rising awareness of genetic diseases, increasing infertility rates, and the growing adoption of assisted reproductive technologies (ART). In addition, technological innovations, such as next-generation sequencing (NGS) and CRISPR-based gene editing, are enhancing the accuracy and efficiency of genetic screening, which is expected to further fuel market growth.
North America is currently the dominant region in the PGT market, supported by a well-established healthcare infrastructure and high demand for fertility treatments. However, the Asia-Pacific region is witnessing rapid expansion, driven by improving healthcare access and rising awareness about genetic testing.
Key Takeaways
- Market Size & Growth: Preimplantation Genetic Testing Market size is expected to be worth around USD 1648.6 Million by 2033 from USD 756.6 Million in 2023, growing at a CAGR of 8.1%.
- By Procedure Type: In 2023, Preimplantation Genetic Diagnosis held approximately 78% of market revenue share.
- By Product Type: In 2023, reagent & consumables represented 50.6% of revenue share.
- By Technology: Polymerase chain reaction (PCR) held the highest revenue share at 40.6% in 2023.
- By Application: Aneuploidy screening dominated the preimplantation genetic testing market in 2023, accounting for 26.8% of its revenue share.
- By End-User: The hospital segment accounted for the highest revenue share of around 40% in 2023.
- Regional Analysis: North America secured 36.4% market share and contributed USD 275.4 Million revenue in 2023.
Segmentation Analysis of Preimplantation Genetic Testing (PGT)
- By Procedure Type: In 2023, Preimplantation Genetic Diagnosis (PGD) held 78% of market revenue and is expected to grow fastest. The rise is due to increasing awareness of genetic testing and its role in detecting gene mutations, reducing genetic diseases in newborns. Additionally, Next-Generation Sequencing (NGS) technology and growing single-gene disease cases have supported this segment’s expansion. Preimplantation Genetic Screening (PGS) is also growing due to advancements in IVF and increased demand.
- By Product Type: Reagents and consumables accounted for 50.6% of revenue in 2023 and are expected to grow fastest due to the increasing use of preimplantation genetic testing (PGT) in IVF, with over 2.7 million annual IVF cycles globally. Instruments held the second-largest share as advanced genetic testing equipment improves accuracy. Expanding hospital and clinic offerings further drive demand for consumables and instruments in IVF procedures.
- By Technology: Polymerase Chain Reaction (PCR) held 40.6% of revenue in 2023 due to its cost-effectiveness, precision, and widespread use. PCR enhances detection of chromosomal abnormalities through its specificity and sensitivity. Next-Generation Sequencing (NGS) is set to grow fastest, offering rapid sequencing of large DNA volumes with higher accuracy. Advances in NGS technology enable detection of additional chromosomal abnormalities, boosting its adoption.
- By Application: Aneuploidy screening dominated with a 26.8% revenue share in 2023, driven by its effectiveness in evaluating embryo quality during IVF. Growing adoption and innovative products fuel its growth. HLA typing ranked second, supporting stem cell therapy through embryo testing, offering higher survival rates for related transplants compared to unrelated donors, solidifying its significance in preimplantation genetic testing.
- By End-User: Hospitals accounted for 40% of revenue in 2023, benefiting from advanced technology, high patient inflow, and robust healthcare infrastructure. Hospitals’ involvement in research also drives higher testing rates. Fertility centers held the second-largest share, supported by improved infrastructure and technological advancements in testing, ensuring steady growth in their role within preimplantation genetic testing.
How Artificial Intelligence (AI) is Changing the Preimplantation Genetic Testing Market?
Artificial Intelligence (AI) is significantly transforming the field of preimplantation genetic testing (PGT) by enhancing the accuracy, efficiency, and predictive capabilities of genetic analyses. The National Institutes of Health (NIH) has emphasized the integration of AI and machine learning approaches in genomic studies, particularly in understanding the genetic factors contributing to pregnancy loss.
One notable advancement is the development of AI-driven tools like GenoML, an end-to-end framework designed to assist researchers in processing genomic datasets. GenoML facilitates tasks such as data pre-processing, model training, and tuning, thereby accelerating the analysis process and improving predictive accuracy.
The World Health Organization (WHO) has also explored the application of AI in sexual and reproductive health, acknowledging its potential to improve accessibility and quality of services. However, the WHO cautions about potential risks, including data privacy concerns, biases in training datasets, and the need for transparent AI system development.
In the context of PGT, AI algorithms are being utilized to analyze embryonic development and genetic data, aiding in the selection of embryos with the highest implantation potential and lowest risk of genetic abnormalities. This integration of AI not only streamlines the testing process but also enhances decision-making accuracy, ultimately contributing to improved outcomes in assisted reproductive technologies.
Emerging Trends
- Non-Invasive Testing Methods: Non-invasive Preimplantation Genetic Testing (PGT) methods are emerging as safer alternatives to traditional techniques. These methods analyze genetic material from embryos without requiring a biopsy. This approach significantly reduces the risks linked to invasive testing. Researchers are exploring the use of cell-free DNA found in culture media as a viable source for genetic analysis. This breakthrough could improve the accuracy and safety of genetic testing in embryos. With ongoing studies, non-invasive PGT methods are poised to revolutionize embryo screening and selection, making genetic testing more accessible and less harmful for patients.
- Polygenic Risk Scores: Polygenic risk scores are a new advancement in genetic research. These scores predict the likelihood of an embryo developing complex diseases, such as diabetes or heart disease, by analyzing multiple genes. This method can provide valuable insights for selecting embryos with lower risks of genetic conditions. However, its accuracy remains under debate, and ethical concerns have been raised. Questions about the fairness and societal impact of using these scores are ongoing. Despite the challenges, polygenic risk scores hold significant potential for advancing genetic testing in the reproductive health sector.
- Ethical and Social Considerations: The growing use of PGT has sparked ethical debates and social concerns. Selecting embryos based on genetic traits raises fears of genetic discrimination and societal inequality. Critics argue that this technology could lead to unintended consequences, such as prioritizing specific traits over others. Discussions are ongoing about ensuring the responsible use of genetic information in reproductive decisions. Policymakers, researchers, and healthcare professionals are working to establish guidelines that balance technological advancements with ethical considerations, aiming to make PGT both effective and equitable for all.
Use Cases
- Non-Invasive Testing Methods: Non-invasive PGT techniques are transforming genetic testing. These methods analyze genetic material from embryos without requiring a biopsy. This reduces risks associated with traditional invasive procedures. Researchers are exploring cell-free DNA from culture media as a reliable source for analysis. This innovation improves safety and accuracy, making genetic testing less stressful for patients. As studies progress, non-invasive PGT methods are expected to become widely adopted, offering a significant breakthrough in embryo screening and selection.
- Polygenic Risk Scores: Polygenic risk scores are advancing genetic research in PGT. These scores predict the chances of embryos developing complex diseases like diabetes or heart disease. By analyzing multiple genes, they provide a broader view of potential risks. However, accuracy concerns and ethical issues remain critical challenges. The use of these scores for embryo selection raises questions about fairness and societal impact. Despite this, polygenic risk scores hold promise for enhancing decision-making in reproductive health.
- Ethical and Social Considerations: The expanding use of PGT has led to ethical and social concerns. Selecting embryos based on genetic traits raises fears of genetic discrimination and societal inequality. Critics worry about prioritizing certain traits, which could have unintended consequences. Discussions are ongoing to address these challenges and promote responsible use of genetic testing. Efforts focus on balancing innovation with ethical considerations, ensuring that advancements in PGT benefit all without compromising fairness or equality.
Conclusion
The Preimplantation Genetic Testing (PGT) market is experiencing substantial growth, driven by advancements in reproductive technologies, rising infertility rates, and increasing awareness of genetic disorders. Technological innovations, including Next-Generation Sequencing (NGS) and AI integration, are enhancing the accuracy and efficiency of genetic screenings. North America currently leads the market, though the Asia-Pacific region is expanding rapidly.
The growth of non-invasive testing methods and polygenic risk scores also promises to reshape the landscape, offering safer and more predictive solutions for embryo selection. However, ethical considerations surrounding genetic testing, such as genetic discrimination and societal inequality, remain critical. Overall, PGT’s continued advancements offer improved fertility outcomes, making it a cornerstone of modern reproductive health.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
